{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:59:14Z","timestamp":1789577954531,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T00:00:00Z","timestamp":1689638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Applied Basic Research Program of Xuzhou","award":["KC19031"],"award-info":[{"award-number":["KC19031"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>According to the latest epidemiology of the US, B-cell cancers account for\u2009&gt;\u20093% of all new cancer cases and\u2009&gt;\u200980% of non-Hodgkin lymphomas. However, the disease-modifying small molecular drug suitable for most B-cell cancers is still lacking. RIPK1 (receptor-interacting serine\/threonine-protein kinase 1) has been observed to be dysregulated and implicated in the pathogenesis of multiple solid cancers, of which, however, the roles in blood cancers are quite unclear. In our study, to identify multi-function targets for B-cell cancer treatment, we reanalyzed a public transcriptomic dataset from the database of Gene Expression Omnibus, which includes CD19<jats:sup>+<\/jats:sup> B-cell populations from 6 normal donors and patients of 5 CLL, 10 FL, and 8 DLBCL. After overlapping three groups (CLL vs. normal, FL vs. normal, and DLBCL vs. normal) of differentially expressed genes (DEGs), we obtained 69 common DEGs, of which 3 were validated by real-time quantitative PCR, including RIPK3, IGSF3, TGFBI. Interestingly, we found that the loss function of RIPK1 significantly increases the proliferation and viability of GM12878 cells (a normal human B lymphocyte cell line). Consistently, overexpression of RIPK1 in TMD8 and U2932 cells effectively inhibited cell proliferation and growth. More importantly, modifying RIPK1 kinase activity by a small molecule (such as necrostain-1, HOIPIN-1, etc.) alters the cell growth status of B-cell lymphoma, showing that RIPK1 exhibits anti-tumor activity in the context of B-cell lymphoma. Taken together, we consider that RIPK1 may be a potential target in the clinical application of B-cell lymphoma (including CLL, DLBCL, and FL) treatment.<\/jats:p>","DOI":"10.1007\/s12672-023-00725-z","type":"journal-article","created":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T10:02:16Z","timestamp":1689674536000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["RIPK1 is aberrantly expressed in multiple B-cell cancers and implicated in the underlying pathogenesis"],"prefix":"10.1007","volume":"14","author":[{"given":"Baoyu","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianguo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong chuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"issue":"10091","key":"725_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","volume":"390","author":"JO Armitage","year":"2017","unstructured":"Armitage JO, et al. Non-HODGKIN LYMPHOMA. The Lancet. 2017;390(10091):298\u2013310.","journal-title":"The Lancet"},{"issue":"1","key":"725_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"725_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-021-01113-2","volume":"14","author":"W Hanel","year":"2021","unstructured":"Hanel W, Epperla N. Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies. J Hematol Oncol. 2021;14(1):104.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"725_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41467-021-27853-w","volume":"13","author":"DP Wong","year":"2022","unstructured":"Wong DP, et al. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun. 2022;13(1):217.","journal-title":"Nat Commun"},{"issue":"17","key":"725_CR5","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020104469","volume":"39","author":"H Ashida","year":"2020","unstructured":"Ashida H, Sasakawa C, Suzuki T. A unique bacterial tactic to circumvent the cell death crosstalk induced by blockade of caspase-8. EMBO J. 2020;39(17): e104469.","journal-title":"EMBO J"},{"issue":"7788","key":"725_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41586-019-1830-y","volume":"577","author":"P Tao","year":"2020","unstructured":"Tao P, et al. A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1. Nature. 2020;577(7788):109\u201314.","journal-title":"Nature"},{"issue":"Suppl 3","key":"725_CR7","first-page":"94","volume":"6","author":"S Yamamoto","year":"2017","unstructured":"Yamamoto S, Iwakuma T. RIPK1-TRAF2 interplay on the TNF\/NF-\u03baB signaling, cell death, and cancer development in the liver. Transl Cancer Res. 2017;6(Suppl 3):94\u2013109.","journal-title":"Transl Cancer Res"},{"issue":"4","key":"725_CR8","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/cdd.2010.138","volume":"18","author":"N Vanlangenakker","year":"2011","unstructured":"Vanlangenakker N, et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis by preventing RIP1\/RIP3-dependent reactive oxygen species production. Cell Death Differ. 2011;18(4):656\u201365.","journal-title":"Cell Death Differ"},{"key":"725_CR9","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a036368","author":"K Newton","year":"2020","unstructured":"Newton K. Multitasking kinase RIPK1 regulates cell death and inflammation. Cold Spring Harb Perspect Biol. 2020. https:\/\/doi.org\/10.1101\/cshperspect.a036368.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"7516","key":"725_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature13706","volume":"513","author":"N Takahashi","year":"2014","unstructured":"Takahashi N, et al. RIPK1 ensures intestinal homeostasis by protecting the epithelium against apoptosis. Nature. 2014;513(7516):95\u20139.","journal-title":"Nature"},{"issue":"10","key":"725_CR11","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1038\/cdd.2016.51","volume":"23","author":"B Shutinoski","year":"2016","unstructured":"Shutinoski B, et al. K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo. Cell Death Differ. 2016;23(10):1628\u201337.","journal-title":"Cell Death Differ"},{"issue":"3","key":"725_CR12","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cell.2019.06.014","volume":"178","author":"DW Vredevoogd","year":"2019","unstructured":"Vredevoogd DW, et al. Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold. Cell. 2019;178(3):585\u201399.","journal-title":"Cell"},{"issue":"705","key":"725_CR13","doi-asserted-by":"publisher","first-page":"eabc4764","DOI":"10.1126\/scisignal.abc4764","volume":"14","author":"G Sriram","year":"2021","unstructured":"Sriram G, et al. The injury response to DNA damage in live tumor cells promotes antitumor immunity. Sci Signal. 2021;14(705):eabc4764.","journal-title":"Sci Signal"},{"issue":"4","key":"725_CR14","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.immuni.2022.03.007","volume":"55","author":"L Cucolo","year":"2022","unstructured":"Cucolo L, et al. The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade. Immunity. 2022;55(4):671-685.e10.","journal-title":"Immunity"},{"issue":"6","key":"725_CR15","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910979","volume":"12","author":"HG Smith","year":"2020","unstructured":"Smith HG, et al. RIPK1-mediated immunogenic cell death promotes anti-tumour immunity against soft-tissue sarcoma. EMBO Mol Med. 2020;12(6): e10979.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"725_CR16","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1080\/15548627.2015.1049800","volume":"11","author":"Q Luan","year":"2015","unstructured":"Luan Q, et al. RIPK1 regulates survival of human melanoma cells upon endoplasmic reticulum stress through autophagy. Autophagy. 2015;11(7):975\u201394.","journal-title":"Autophagy"},{"issue":"1","key":"725_CR17","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12885-020-06779-4","volume":"20","author":"Z Tuoheti","year":"2020","unstructured":"Tuoheti Z, et al. RIPK1 polymorphisms alter the susceptibility to cervical Cancer among the Uyghur population in China. BMC Cancer. 2020;20(1):299.","journal-title":"BMC Cancer"},{"issue":"8","key":"725_CR18","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/s41419-018-0851-z","volume":"9","author":"M Akimoto","year":"2018","unstructured":"Akimoto M, et al. Antidiabetic adiponectin receptor agonist AdipoRon suppresses tumour growth of pancreatic cancer by inducing RIPK1\/ERK-dependent necroptosis. Cell Death Dis. 2018;9(8):804.","journal-title":"Cell Death Dis"},{"issue":"2","key":"725_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.jcmgh.2020.10.009","volume":"11","author":"A Di Grazia","year":"2021","unstructured":"Di Grazia A, et al. The fragile X mental retardation protein regulates RIPK1 and colorectal cancer resistance to necroptosis. Cell Mol Gastroenterol Hepatol. 2021;11(2):639\u201358.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"725_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004031","author":"L Nicol\u00e8","year":"2022","unstructured":"Nicol\u00e8 L, et al. Necroptosis-driving genes RIPK1, RIPK3 and MLKL-p are associated with intratumoral CD3(+) and CD8(+) T cell density and predict prognosis in hepatocellular carcinoma. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-004031.","journal-title":"J Immunother Cancer."},{"issue":"1","key":"725_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.molmed.2018.10.007","volume":"25","author":"V Kondylis","year":"2019","unstructured":"Kondylis V, Pasparakis M. RIP Kinases in liver cell death, inflammation and cancer. Trends Mol Med. 2019;25(1):47\u201363.","journal-title":"Trends Mol Med"},{"issue":"8","key":"725_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.it.2016.06.002","volume":"37","author":"AT Ting","year":"2016","unstructured":"Ting AT, Bertrand MJM. More to Life than NF-kappaB in TNFR1 Signaling. Trends Immunol. 2016;37(8):535\u201345.","journal-title":"Trends Immunol"},{"key":"725_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105297","volume":"163","author":"L Cao","year":"2021","unstructured":"Cao L, Mu W. Necrostatin-1 and necroptosis inhibition: pathophysiology and therapeutic implications. Pharmacol Res. 2021;163: 105297.","journal-title":"Pharmacol Res"},{"issue":"1","key":"725_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/cvr\/cvt078","volume":"99","author":"D Feyen","year":"2013","unstructured":"Feyen D, et al. Increasing short-term cardiomyocyte progenitor cell (CMPC) survival by necrostatin-1 did not further preserve cardiac function. Cardiovasc Res. 2013;99(1):83\u201391.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"725_CR25","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.bbrc.2020.03.177","volume":"526","author":"S Liang","year":"2020","unstructured":"Liang S, Nian Z, Shi K. Inhibition of RIPK1\/RIPK3 ameliorates osteoclastogenesis through regulating NLRP3-dependent NF-kappaB and MAPKs signaling pathways. Biochem Biophys Res Commun. 2020;526(4):1028\u201335.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"725_CR26","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.molcel.2018.01.027","volume":"69","author":"A Annibaldi","year":"2018","unstructured":"Annibaldi A, et al. Ubiquitin-mediated regulation of RIPK1 kinase activity independent of IKK and MK2. Mol Cell. 2018;69(4):566-580.e5.","journal-title":"Mol Cell"},{"issue":"1","key":"725_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/cdd.2011.163","volume":"19","author":"M Darding","year":"2012","unstructured":"Darding M, Meier P. IAPs: guardians of RIPK1. Cell Death Differ. 2012;19(1):58\u201366.","journal-title":"Cell Death Differ"},{"issue":"9","key":"725_CR28","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1042\/BCJ20210725","volume":"479","author":"E Varfolomeev","year":"2022","unstructured":"Varfolomeev E, Vucic D. RIP1 post-translational modifications. Biochem J. 2022;479(9):929\u201351.","journal-title":"Biochem J"},{"issue":"10","key":"725_CR29","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1177\/2472555218793066","volume":"23","author":"K Katsuya","year":"2018","unstructured":"Katsuya K, et al. High-throughput screening for linear ubiquitin chain assembly complex (LUBAC) selective inhibitors using homogenous time-resolved fluorescence (HTRF)-based assay system. SLAS Discov. 2018;23(10):1018\u201329.","journal-title":"SLAS Discov"},{"issue":"3","key":"725_CR30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/cdd.2016.147","volume":"24","author":"MC Tanzer","year":"2017","unstructured":"Tanzer MC, et al. Combination of IAP antagonist and IFN\u03b3 activates novel caspase-10- and RIPK1-dependent cell death pathways. Cell Death Differ. 2017;24(3):481\u201391.","journal-title":"Cell Death Differ"},{"issue":"3","key":"725_CR31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41419-019-1490-8","volume":"10","author":"X Zhang","year":"2019","unstructured":"Zhang X, Dowling JP, Zhang J. RIPK1 can mediate apoptosis in addition to necroptosis during embryonic development. Cell Death Dis. 2019;10(3):245.","journal-title":"Cell Death Dis"},{"key":"725_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.07.007","author":"T Zhang","year":"2022","unstructured":"Zhang T, et al. Necroptosis pathways in tumorigenesis. Semin Cancer Biol. 2022. https:\/\/doi.org\/10.1016\/j.semcancer.2022.07.007.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"725_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41523-021-00261-5","volume":"7","author":"Z Yin","year":"2021","unstructured":"Yin Z, et al. RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasis. NPJ Breast Cancer. 2021;7(1):53.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"725_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41419-021-04483-0","volume":"13","author":"YQ Yu","year":"2022","unstructured":"Yu YQ, et al. SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth. Cell Death Dis. 2022;13(1):52.","journal-title":"Cell Death Dis"},{"issue":"3","key":"725_CR35","first-page":"2807","volume":"18","author":"T Fang","year":"2018","unstructured":"Fang T, et al. Alterations in necroptosis during ALDH2mediated protection against high glucoseinduced H9c2 cardiac cell injury. Mol Med Rep. 2018;18(3):2807\u201315.","journal-title":"Mol Med Rep"},{"issue":"1","key":"725_CR36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3892\/ijmm.2017.3006","volume":"40","author":"W Liang","year":"2017","unstructured":"Liang W, et al. A novel damage mechanism: contribution of the interaction between necroptosis and ROS to high glucose-induced injury and inflammation in H9c2 cardiac cells. Int J Mol Med. 2017;40(1):201\u20138.","journal-title":"Int J Mol Med"},{"issue":"1","key":"725_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.15252\/emmm.201606566","volume":"9","author":"SH Yang","year":"2017","unstructured":"Yang SH, et al. Nec-1 alleviates cognitive impairment with reduction of Abeta and tau abnormalities in APP\/PS1 mice. EMBO Mol Med. 2017;9(1):61\u201377.","journal-title":"EMBO Mol Med"},{"issue":"3","key":"725_CR38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tcb.2019.12.009","volume":"30","author":"T Delanghe","year":"2020","unstructured":"Delanghe T, Dondelinger Y, Bertrand MJM. RIPK1 Kinase-dependent death: a symphony of phosphorylation events. Trends Cell Biol. 2020;30(3):189\u2013200.","journal-title":"Trends Cell Biol"},{"issue":"3","key":"725_CR39","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.bbrc.2018.12.164","volume":"509","author":"K Katsuya","year":"2019","unstructured":"Katsuya K, et al. Small-molecule inhibitors of linear ubiquitin chain assembly complex (LUBAC), HOIPINs, suppress NF-kappaB signaling. Biochem Biophys Res Commun. 2019;509(3):700\u20136.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00725-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-023-00725-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00725-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T10:13:05Z","timestamp":1689675185000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-023-00725-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1007\/s12672-023-00725-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]},"assertion":[{"value":"13 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}